Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Rare CNS Tumor Recurrent: early-phase trial registry

1 of 1 indexed Rare CNS Tumor Recurrent trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Rare CNS Tumor Recurrent: 1 US clinical trial tracked, 1 recruiting.

Rare CNS Tumor Recurrent is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Medical University of Vienna, running 1 of these trials.

Enrollment posture brief

Registry condition rare-cns-tumor-recurrent

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Rare CNS Tumor Recurrent (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Rare CNS Tumor Recurrent

Rare CNS Tumor Recurrent lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Rare CNS Tumor Recurrent on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Rare CNS Tumor Recurrent is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Rare CNS Tumor Recurrent records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Fenofibric acid Drug
1 trials
Thalidomide Drug
1 trials
Celecoxib Drug
1 trials
Etoposide Drug
1 trials
Bevacizumab Drug
1 trials

US sites by state

Facility locations filed on Rare CNS Tumor Recurrent trials. A trial with sites in several states counts in each.

Texas 1 trials
Michigan 1 trials
Massachusetts 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Rare CNS Tumor Recurrent page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Rare CNS Tumor Recurrent condition card totals 1 registered trials; most-linked intervention Fenofibric acid; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.